{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:22:47Z","timestamp":1771867367995,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.vaccine.2017.07.056","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T13:44:53Z","timestamp":1501595093000},"page":"5470-5476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Emerging clinical experience with vaccines against group B meningococcal disease"],"prefix":"10.1016","volume":"36","author":[{"given":"A.L.","family":"Wilkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Snape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2017.07.056_b0005","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1473-3099(15)00217-0","article-title":"Global incidence of serogroup B invasive meningococcal disease: a systematic review","volume":"15","author":"Sridhar","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.056_b0010","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV) Lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2017.07.056_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00121","article-title":"Bacterial outer membrane vesicles and vaccine applications","volume":"5","author":"Acevedo","year":"2014","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.056_b0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1473-3099(09)70324-X","article-title":"Serogroup B meningococcal vaccines-an unfinished story","volume":"10","author":"Sadarangani","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.056_b0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.056_b0030","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.07.056_b0035","first-page":"195","article-title":"Vaccine against group B Neisseria Meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"issue":"9","key":"10.1016\/j.vaccine.2017.07.056_b0040","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.056_b0045","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.056_b0050","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo","volume":"340","author":"Moraes","year":"1992","journal-title":"Brazil Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.056_b0055","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/ije\/24.5.1050","article-title":"Assessment of the direct effectiveness of BC meningococcal vaccine in Rio De Janeiro, Brazil: a case-control study","volume":"24","author":"Noronha","year":"1995","journal-title":"Int J Epidemiol"},{"issue":"16","key":"10.1016\/j.vaccine.2017.07.056_b0060","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 Serogroup B outer-membrane protein meningococcal vaccines","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA."},{"issue":"40","key":"10.1016\/j.vaccine.2017.07.056_b0065","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2011.06.120","article-title":"Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand","volume":"29","author":"Arnold","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2017.07.056_b0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1586\/14760584.2013.814862","article-title":"A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?","volume":"12","author":"Martin","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.07.056_b0075","unstructured":"Novartis Pharmaceutical Canada Inc. Bexsero Product Information [Internet]. 2015 [cited 2017 Jan 9]. p. 1\u201346. Available from: https:\/\/ca.gsk.com\/media\/1212390\/bexsero.pdf."},{"key":"10.1016\/j.vaccine.2017.07.056_b0080","unstructured":"Therapeutic Good Administration. Bexsero Product and Consumer Medicine Information [Internet]. [cited 2017 Jan 9]. p. 1\u201318. Available from: https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/PICMI?OpenForm&t=pi&q=bexsero."},{"key":"10.1016\/j.vaccine.2017.07.056_b0085","unstructured":"US Food and Drug Administration. Bexsero Full Prescribing Information [Internet]. 2015 [cited 2017 Jan 9]. p. 1\u201311. Available from: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm431374.htm."},{"issue":"9869","key":"10.1016\/j.vaccine.2017.07.056_b0090","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.056_b0095","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/INF.0000000000001056","article-title":"Persistence of bactericidal antibodies after infant Serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 months of age","volume":"35","author":"Snape","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"10.1016\/j.vaccine.2017.07.056_b0100","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal Serogroup B vaccine with and without outer membrane vesicles administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.056_b0105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.vaccine.2016.11.009","article-title":"Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial","volume":"35","author":"Iro","year":"2017","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.vaccine.2017.07.056_b0110","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2017.05.023","article-title":"Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open- label phase 3b trial","volume":"35","author":"Martin\u00f3n-Torres","year":"2017","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2017.07.056_b0115","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.056_b0120","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.07.056_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(17)30170-6","article-title":"Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007\u201308 and 2014\u201315: a qualitative and quantitative assessment","author":"Parikh","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"43","key":"10.1016\/j.vaccine.2017.07.056_b0130","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.056_b0135","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.vaccine.2016.04.009","article-title":"Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB","volume":"34","author":"Budroni","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.056_b0140","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1016\/j.vaccine.2016.08.015","article-title":"Distribution of Bexsero\u00ae Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation","volume":"34","author":"Brehony","year":"2016","journal-title":"Vaccine."},{"issue":"5","key":"10.1016\/j.vaccine.2017.07.056_b0145","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","article-title":"First use of a Serogroup B meningococcal vaccine in the US in response to a university outbreak","volume":"135","author":"Mcnamara","year":"2015","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.056_b0150","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1514866","article-title":"Immunogenicity of a Meningococcal B vaccine during a university outbreak","volume":"375","author":"Basta","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.07.056_b0155","unstructured":"Patel M. Outbreak of serogroup B meningococcal disease on university campuses \u2013 2013. Meningitis and Vaccine Preventable Disease Branch, Centers for Disease Control and Prevention [Internet]. Advisory Committee on Immunization Practices (ACIP). 2014 [cited 2017 Oct 16]. Available from: http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/min-archive\/min-2014-02.pdf."},{"key":"10.1016\/j.vaccine.2017.07.056_b0160","series-title":"Initial dose of a multicomponent Serogroup B Meningococcal vaccine in the saguenay\u2013 Lac-Saint-Jean Region, Qu\u00e9bec","author":"De Serres","year":"2014"},{"key":"10.1016\/j.vaccine.2017.07.056_b0165","unstructured":"de Wals P. Results of a mass immunisation campaign with 4-components serogroup b meningococcal vaccine (4CMenB) in Quebec, Canada [Internet]. Meningitis Research Foundation Conference: Meningitis and Septicaemia in Chidlren and Adults. 2015 [cited 2016 Nov 14]. Available from: http:\/\/www.meningitis.org\/conference2015#Wals."},{"key":"10.1016\/j.vaccine.2017.07.056_b0170","unstructured":"Public Health England. Meningococcal. In: Green Book. v6.1. 2016. p. 295\u2013311."},{"key":"10.1016\/j.vaccine.2017.07.056_b0175","unstructured":"Health Service Executive (HSE) Ireland. Meningococcal Infection [Internet]. HSE Immunisation Guidelines. 2016 [cited 2016 Oct 17]. p. 1\u201320. Available from: http:\/\/www.hse.ie\/eng\/health\/immunisation\/hcpinfo\/guidelines\/chapter13.pdf."},{"key":"10.1016\/j.vaccine.2017.07.056_b0180","first-page":"125","article-title":"Meningococcal serogroup B vaccine in Italy : state-of-art, organizational aspects and perspectives","volume":"56","author":"Signorelli","year":"2015","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2017.07.056_b0185","unstructured":"Czech Vaccination Society. Czech Vaccination Society recommendation for vaccination against invasive meningococcal disease [Internet]. 2014 [cited 2017 Jan 9]. Available from: http:\/\/www.szu.cz\/uploads\/IMO\/Recommendation_for_vaccination_IMD.pdf."},{"key":"10.1016\/j.vaccine.2017.07.056_b0190","unstructured":"Australian Technical Advisory Group on Immunisation (ATAGI) Australian Government Department of Health. Australian Technical Advisory Group on Immunisation (ATAGI) Statement Advice for immunisation providers regarding the use of Bexsero \u00ae \u2013 a recombinant multicomponent meningococcal B vaccine (4CMenB) March 2014 Meningococci and meningococcal disease [Internet]. 2014 [cited 2017 Jan 16]. p. 6\u201313. Available from: http:\/\/www.immunise.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/atagi-advice-bexsero."},{"key":"10.1016\/j.vaccine.2017.07.056_b0195","unstructured":"Pharmaceutical Benefits Advisory Committee. Multi-component meningococcal group B vaccine. Public Summary Documents PBAC Meeting July 2015 [Internet]. 2015 [cited 2016 Oct 17]. Available from: https:\/\/www.pbs.gov.au\/pbs\/industry\/listing\/elements\/pbac-meetings\/psd\/2015-07\/mulit-component-meningococcal-group-b-vaccine-psd-july-2015."},{"key":"10.1016\/j.vaccine.2017.07.056_b0200","unstructured":"HAS Medical Economic and Public Health Assessment Division. Transparency Committee Opinion for Bexsero recommended use in France [Internet]. 2014 [cited 2017 Jan 9]. p. 1\u201321. Available from: http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2015-09\/bexsero_en_ct13508_val.pdf."},{"key":"10.1016\/j.vaccine.2017.07.056_b0205","first-page":"327","article-title":"Statement of the German standing committee on vaccination at the robert koch insitut: recommendations of the standing committee on vaccination (STIKO) at the robert koch institute\/effective: august 2015","volume":"34","author":"Robert Koch Insitiut","year":"2015","journal-title":"Epidemiol Bull Curr Data Inf Infect Dis Public Heal"},{"key":"10.1016\/j.vaccine.2017.07.056_b0210","unstructured":"Centers for Disease Control and Prevention. Vaccine Information Statement Serogroup B Meningococcal Vaccine (MenB): What You Need to Know [Internet]. 2016 [cited 2017 Jan 9]. p. 1\u20132. Available from: https:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/mening-serogroup.html."},{"key":"10.1016\/j.vaccine.2017.07.056_b0215","unstructured":"Public Health England. Meningococcal disease: laboratory confirmed cases in England, quarterly reports [Internet]. 2016 [cited 2017 Mar 12]. Available from: https:\/\/www.gov.uk\/government\/publications\/meningococcal-disease-laboratory-confirmed-cases-in-england-and-wales."},{"key":"10.1016\/j.vaccine.2017.07.056_b0220","unstructured":"Joint Committee on Vaccination and Immunisation. JCVI position statement on use of Bexsero\u00ae meningococcal B vaccine in the UK March 2014 [Internet]. 2014. Available from: https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/294245\/JCVI_Statement_on_MenB.pdf."},{"issue":"16","key":"10.1016\/j.vaccine.2017.07.056_b0225","first-page":"1","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England : a national observational cohort study","volume":"6736","author":"Parikh","year":"2016","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.056_b0230","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.vaccine.2016.11.076","article-title":"Modelling the cost-effectiveness of catch-up \u201c MenB \u201d (Bexsero) vaccination in England","volume":"35","author":"Christensen","year":"2017","journal-title":"Vaccine."},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.056_b0235","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicty and tolerability of recombinant Serogroup B Meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules","volume":"307","author":"Gossger","year":"2012","journal-title":"J Am Med Assoc"},{"issue":"7","key":"10.1016\/j.vaccine.2017.07.056_b0240","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.4161\/hv.28666","article-title":"A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine","volume":"10","author":"Prymula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.07.056_b0245","unstructured":"Nainani V, Buttery J, Snape M. Oral abstract: Presentation to Accident and Emergency following immunization with capsular group B meningococcal vaccine [Internet]. International Pathogenic Neisseria Conference. 2016 [cited 2016 Nov 15]. Available from: http:\/\/www.ipnc2016.org\/IPNC2016AbstractBook.pdf."},{"key":"10.1016\/j.vaccine.2017.07.056_b0250","unstructured":"Harcourt S, Morbey R, Smith G, Ladhani S, Bates C, Carter H, et al. Using Syndromic surveillance to assess whether there has been an increase in fever consultations in infants following the introduction of the Meningococcal B vaccination [Internet]. Public Health England Annual Conference. 2016 [cited 2017 May 31]. Available from: https:\/\/www.phe-events.org.uk\/hpa\/frontend\/reg\/absViewDocumentFE.csp%3FdocumentID%3D10459."},{"issue":"1","key":"10.1016\/j.vaccine.2017.07.056_b0255","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jinf.2015.02.006","article-title":"Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy","volume":"71","author":"Jeppesen","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2017.07.056_b0260","unstructured":"ClinicalTrials.gov. South Australian Meningococcal B Vaccine Herd Immunity Study (B Part of It) [Internet]. 2017 [cited 2017 Jun 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03089086."},{"key":"10.1016\/j.vaccine.2017.07.056_b0265","unstructured":"Research Design Service South East NHS National Institute for Health Research. Research Design Department of Health Policy Research Programme \u2013 new calls [Internet]. 2017 [cited 2017 Jun 6]. Available from: http:\/\/www.rds-se.nihr.ac.uk\/latest-news\/department-of-health-policy-research-programme-new-calls\/%0D."},{"key":"10.1016\/j.vaccine.2017.07.056_b0270","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2017.07.056_b0275","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.vaccine.2016.11.071","article-title":"A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B mening","volume":"35","author":"Read","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2017.07.056_b0280","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in england and wales","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2017.07.056_b0285","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.vaccine.2016.02.014","article-title":"Global epidemiology of capsular group W meningococcal disease (1970\u20132015): multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex","volume":"34","author":"Mustapha","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.056_b0290","doi-asserted-by":"crossref","unstructured":"Campbell H, Edelstein M, Andrews N, Borrow R, Ramsay M, Ladhani S. Emergency Meningococcal ACWY Vaccination Program for Teenagers to Control Group W Meningococcal Disease, England, 2015\u20132016 [Internet]. Vol. 23, Emerging Infectious Disease journal. 2017 [cited 2017 May 2]. Available from: http:\/\/wwwnc.cdc.gov\/eid\/article\/23\/7\/17-0236.","DOI":"10.3201\/eid2307.170236"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.056_b0295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3201\/eid2202.150369","article-title":"Effectiveness of meningococcal B vaccine against endemic hypervirulent neisseria meningitidis W strain England","volume":"22","author":"Ladhani","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2017.07.056_b0300","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2017.07.056_b0305","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba\u00ae)","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.vaccine.2017.07.056_b0310","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1473-3099(16)30314-0","article-title":"Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Marshall","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2017.07.056_b0315","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/INF.0000000000001399","article-title":"Neisseria meningitidis Serogroup B vaccine, Bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains","volume":"36","author":"Harris","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"40","key":"10.1016\/j.vaccine.2017.07.056_b0320","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.vaccine.2014.07.049","article-title":"A randomized, phase 1\/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants","volume":"32","author":"Martinon-Torres","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.07.056_b0325","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics. Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older. Pediatrics. 2016;138(3):e20161890.","DOI":"10.1542\/peds.2016-1890"},{"key":"10.1016\/j.vaccine.2017.07.056_b0330","unstructured":"US Food and Drug Administration. Trumenba (Meningococcal Group B Vaccine) Highlights of Prescribing Information [Internet]. 2014 [cited 2016 Oct 31]. p. 1\u201311. Available from: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM421139.pdf."},{"key":"10.1016\/j.vaccine.2017.07.056_b0335","unstructured":"European Medicines Agency. Trumenba - meningococcal group B vaccine (recombinant, adsorbed) [Internet]. 2017 [cited 2017 Jun 12]. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/004051\/human_med_002101.jsp&mid=WC0b01ac058001d124."},{"issue":"8","key":"10.1016\/j.vaccine.2017.07.056_b0340","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/cid\/cix091","article-title":"Meningococcal carriage evaluation in response to a Serogroup B meningococcal disease outbreak and mass vaccination campaign at a college \u2014 Rhode Island, 2015\u20132016","volume":"64","author":"Soeters","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17309647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17309647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T22:23:35Z","timestamp":1569968615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17309647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":68,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0264410X17309647"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging clinical experience with vaccines against group B meningococcal disease","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}